CN110996965A - 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物 - Google Patents

稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物 Download PDF

Info

Publication number
CN110996965A
CN110996965A CN201880036512.XA CN201880036512A CN110996965A CN 110996965 A CN110996965 A CN 110996965A CN 201880036512 A CN201880036512 A CN 201880036512A CN 110996965 A CN110996965 A CN 110996965A
Authority
CN
China
Prior art keywords
aspirin
water
liquid composition
containing liquid
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880036512.XA
Other languages
English (en)
Chinese (zh)
Inventor
N·R·帕利普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoshan Pharmaceutical Co ltd
Original Assignee
Luoshan Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoshan Pharmaceutical Co ltd filed Critical Luoshan Pharmaceutical Co ltd
Priority to CN202310937648.0A priority Critical patent/CN117379443A/zh
Publication of CN110996965A publication Critical patent/CN110996965A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880036512.XA 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物 Pending CN110996965A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310937648.0A CN117379443A (zh) 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512367P 2017-05-30 2017-05-30
US62/512,367 2017-05-30
PCT/US2018/034866 WO2018222583A1 (en) 2017-05-30 2018-05-29 In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310937648.0A Division CN117379443A (zh) 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物

Publications (1)

Publication Number Publication Date
CN110996965A true CN110996965A (zh) 2020-04-10

Family

ID=64455035

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880036512.XA Pending CN110996965A (zh) 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物
CN202310937648.0A Pending CN117379443A (zh) 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310937648.0A Pending CN117379443A (zh) 2017-05-30 2018-05-29 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物

Country Status (6)

Country Link
US (4) US11096949B2 (https=)
EP (1) EP3630120A4 (https=)
JP (3) JP7335232B2 (https=)
CN (2) CN110996965A (https=)
CA (1) CA3064012A1 (https=)
WO (1) WO2018222583A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096949B2 (en) * 2017-05-30 2021-08-24 Rhoshan Pharmaceuticals, Inc. In-vial deposition of a stable, sterile and crystalline O-acetyl salicylic acid
US11793748B1 (en) 2019-04-05 2023-10-24 Good Health, Llc Pharmaceutical compositions of aspirin for parenteral administration
WO2023198294A1 (en) 2022-04-14 2023-10-19 Hyloris Developments Sa Acetyl salicylic acid composition for intravenous administration, its storage, production and use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066115A2 (de) * 2000-03-07 2001-09-13 Bayer Aktiengesellschaft Acetylsalicylsäure-lösungen
US20020091108A1 (en) * 2000-07-18 2002-07-11 Gerhard Franckowiak Stable salts of O-acetylsalicylic acid with basic amino acids

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB912894A (en) 1959-11-02 1962-12-12 Guy Leopold Van Moorleghem Method for the preparing a solution of aspirin for injection and product obtained thereby
GB993682A (en) * 1962-07-09 1965-06-02 Haessle Ab Salts of acetylsalicylic acid, their production and pharmaceutical preparations containing them
JPS4856815A (https=) * 1971-11-13 1973-08-09
US4117603A (en) * 1976-12-28 1978-10-03 Smith Walton J High vacuum freeze-drying
CA1131245A (en) 1978-07-12 1982-09-07 Walton J. Smith Freeze dried pharmaceuticals
JPS5610110A (en) 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
US4975269A (en) 1989-07-31 1990-12-04 Leonard Chavkin Shelf stable aspirin solutions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
WO1999003474A1 (de) 1997-07-15 1999-01-28 Walter Burghart Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen
TR200100024T2 (tr) * 1998-07-09 2001-06-21 Galat Alexander Enjektabl sodyum asetilsalisilat bileşimi ve yöntemi.
ES2189639B1 (es) * 2001-05-22 2005-02-01 Jesus Angel Hernandez Cordon Composicion acuosa que contiene acido acetilsalicilico.
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR20070034451A (ko) * 2003-10-10 2007-03-28 오릭세 저분자량 및 고분자량 화합물의 경피전달을 위한 혼합물
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
WO2006042662A1 (de) 2004-10-15 2006-04-27 Heidelberg Pharma Gmbh Parenterale darreichungsformen von imexon sowie verfahren zu deren herstellung
DE102005025283A1 (de) 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7202229B1 (en) 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US8481600B2 (en) * 2007-05-16 2013-07-09 Academic Pharmaceuticals, Inc. Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral administration for the treatment of cardiovascular and other disease states
DE202007007241U1 (de) * 2007-05-21 2007-09-20 Temmen Gmbh Krebsprävention an Säugern durch Aktivierung embryonaler Zellen im Verlaufe der ontogenetischen Entwicklung mit Hilfe von Zellwachstumsregulatoren (Auxine) in Kombination mit einem Trägerstoff aus Phospholipiden und Pflanzenölen
WO2010141711A1 (en) * 2009-06-03 2010-12-09 Ex-Tek, Llc Skin treatment compositions
KR20120050437A (ko) 2009-06-25 2012-05-18 테트라, 시아 신규한 아세틸살리실산 염들
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
RO128007A2 (ro) * 2011-06-01 2012-12-28 Institutul Naţional De Cercetare-Dezvoltare Pentru Tehnologii Izotopice Şi Moleculare Procedeu de obţinere a ansamblurilor funcţionale micro/nano-structurate de chitosan şi substanţe active antiinflamatoare prin autoasamblare simultană
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
JP6097446B2 (ja) * 2013-05-30 2017-03-15 ハイアール グループ コーポレーション 野菜の鮮度保持用又は栽培用箱、及び、野菜の生態的鮮度保持方法
WO2014210543A1 (en) * 2013-06-28 2014-12-31 Rexahn Pharmaceuticals, Inc. Nanoparticulate compositions and formulations of piperazine compounds
US9553620B2 (en) * 2014-07-16 2017-01-24 Raytheon Company Signal detection and characterization
CN104546680A (zh) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 一种阿司匹林组合物冻干片及其制备方法
CN104546678A (zh) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 一种阿司匹林组合物冻干片及其制备方法
DE102015002709A1 (de) 2015-03-04 2016-09-08 Cfso Gmbh Neue Verwendung von Acetylsalicylsäure und einem Derivat davon
US11096949B2 (en) * 2017-05-30 2021-08-24 Rhoshan Pharmaceuticals, Inc. In-vial deposition of a stable, sterile and crystalline O-acetyl salicylic acid
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066115A2 (de) * 2000-03-07 2001-09-13 Bayer Aktiengesellschaft Acetylsalicylsäure-lösungen
US20020091108A1 (en) * 2000-07-18 2002-07-11 Gerhard Franckowiak Stable salts of O-acetylsalicylic acid with basic amino acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIRK L. TEAGARDEN等: "Practical aspects of lyophilization using non-aqueous co-solvent systems", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》 *
MARK D. EDDLESTON等: "Cocrystallization by Freeze-Drying: Preparation of Novel Multicomponent Crystal Forms", 《CRYSTAL GROWTH & DESIGN》 *
SÉVERINE VESSOT等: "A Review on Freeze Drying of Drugs with tert-Butanol (TBA)+Water Systems: Characteristics, Advantages, Drawbacks", 《DRYING TECHNOLOGY》 *
SUSANA TORRADO等: "Characterization of Physical State of Mannitol after Freeze-Drying: Effect of Acetylsalicylic Acid as a Second Crystalline Cosolute", 《CHEMICAL & PHARMACEUTICAL BULLETIN》 *

Also Published As

Publication number Publication date
EP3630120A1 (en) 2020-04-08
JP2023116657A (ja) 2023-08-22
JP7335232B2 (ja) 2023-08-29
US10959955B1 (en) 2021-03-30
CA3064012A1 (en) 2018-12-06
US20220409636A1 (en) 2022-12-29
EP3630120A4 (en) 2021-01-13
US20200188417A1 (en) 2020-06-18
CN117379443A (zh) 2024-01-12
JP2020522577A (ja) 2020-07-30
US11911400B1 (en) 2024-02-27
WO2018222583A1 (en) 2018-12-06
US11096949B2 (en) 2021-08-24
JP2025163015A (ja) 2025-10-28
US12048708B2 (en) 2024-07-30

Similar Documents

Publication Publication Date Title
JP2025163015A (ja) 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
ES2259289T3 (es) Formulacion de benzamida con actividad inhibidora de la histona desacetilasa.
ES2258661T3 (es) Formulaciones farmaceuticas con un derivado de platino.
RU2643762C2 (ru) Лиофилизированные препараты мелфалана флуфенамида
KR101808895B1 (ko) 세포독성 디펩티드의 동결건조 제제
TWI764996B (zh) 含西里帕格之醫藥組成物
ES2771227T3 (es) Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C
CH695185A5 (fr) Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame et procede pour leur production.
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP6942182B2 (ja) カルグルミン酸を含有する非経口的薬剤配合物
ES2641889T3 (es) Formulaciones de diclofenaco y métodos de uso
NL1023790C2 (nl) Farmaceutische samenstellingen met antibiotische activiteit.
ES2286177T3 (es) Procedimiento para la preparacion de piroxicam: compuestos de inclusion de betaciclodextrina.
ES2657944T3 (es) Sal estable de arginina de pemetrexed y composiciones que la comprenden
AU2018294561B2 (en) New oral formulations of belinostat
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
KR102667351B1 (ko) 사쿠비트릴 및 아질사르탄 공형성화물, 및 이를 포함하는 약제학적 조성물
ES2360759T3 (es) Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
CN101926780B (zh) 稳定的蒽环类化合物的冻干制剂
JPH0321252A (ja) シスプラチン高張液
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
WO2023214433A1 (en) Stable parenteral compositions of parecoxib
MXPA06006079A (en) Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination